Opdivo scores sixth approval in Japan

Opdivo (nivolumab) has been approved in Japan for unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy.

The Bristol-Myers Squibb and Ono Pharmaceutical drug is the first immuno-oncology agent anywhere to receive approval in this indication based on a Phase III study. Opdivo is now approved to treat six different cancer types in Japan.